Polyrizon Ltd. (PLRZ) Stock Price & How to Invest
Short answer
You can invest in Polyrizon Ltd. (PLRZ) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Polyrizon is a development-stage Israeli biotech developing intranasal hydrogel sprays, led by its NASARIX (PL-14) allergy blocker and a broader nasal drug-delivery platform, with no approved products and no revenue. The thesis is that a non-invasive nasal barrier could address allergies and viral exposure, but the biggest risks are stark: this is a tiny, pre-revenue micro-cap whose products are early-stage, whose survival depends on raising more money, and whose shares can be extremely volatile. Treat it as highly speculative.
PLRZ stock price
As of 2026-06-26, Polyrizon Ltd. (PLRZ) last closed at $11.48, up 158.9% over the past year. Over the past 52 weeks it has traded between $3.13 and $17.17.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Polyrizon Ltd.'s investor relations page. Walnut is informational, not investment advice.
What does Polyrizon Ltd. (PLRZ) do?
Polyrizon Ltd. is a development-stage biotechnology company based in Israel that develops intranasal hydrogel products delivered as nasal sprays. Its proprietary Capture and Contain (C&C) technology is designed to form a thin hydrogel barrier in the nasal cavity, intended to act as a kind of biological shield against allergens and airborne viruses, while its Trap and Target (T&T) platform aims to improve nasal delivery and retention of drugs. The lead program is NASARIX (PL-14), an allergy blocker, alongside earlier-stage candidates such as a viral-blocker program. The company has no approved products and generates no product revenue.
Polyrizon completed its IPO on the Nasdaq Capital Market in October 2024, raising roughly $4.2 million in gross proceeds at $4.38 per unit, and has since raised additional capital. Through 2025 and into 2026 it advanced NASARIX toward the clinic, signing multiple U.S. clinical sites for a planned allergic-rhinitis study, arranging a human nasal-residence-time study at a European medical center, beginning a usability study program, and pursuing an FDA pre-submission pathway. Financially it remains a research-stage company: it reported an operating loss of roughly $6.2 million for 2025 and ended the year with about $17.5 million in cash and no debt, but it has also navigated a Nasdaq listing compliance process, cancelled a previously announced reverse split, and filed a shelf registration for up to $50 million, all of which point to meaningful future dilution risk.
What's driving Polyrizon Ltd. (PLRZ)?
1. Differentiated non-invasive approach.
Polyrizon's Capture and Contain hydrogel is designed to form a temporary protective barrier in the nasal cavity without injections or systemic drugs. If validated, a simple over-the-counter-style nasal spray that reduces allergen or pathogen contact could be attractive for convenience and safety. The concept is novel, but it remains unproven in large, controlled human trials.
2. Lead program moving toward the clinic.
NASARIX (PL-14), the allergy blocker, is the company's most advanced asset and the main near-term driver. During 2026 Polyrizon signed U.S. clinical sites for a seasonal allergic-rhinitis study, arranged a human nasal-residence-time study, and pursued an FDA pre-submission. Progress on these steps is what investors watch most closely, though clinical results are still pending.
3. Platform optionality beyond one product.
Beyond NASARIX, the Trap and Target drug-delivery platform and a viral-blocker concept give Polyrizon more than a single shot on goal, and management has highlighted patent filings to protect the technology. A platform that could be applied across allergy, infection, and intranasal drug delivery offers multiple potential uses, but each would require its own lengthy development and funding.
4. Cash on hand for near-term work.
Polyrizon ended 2025 with roughly $17.5 million in cash and no debt, a meaningful cushion relative to its size that can fund near-term studies. That runway is finite against ongoing losses, and the company has a shelf registration in place, so additional raises and dilution are likely before any product reaches the market.
What are the risks to Polyrizon Ltd. (PLRZ)?
Polyrizon is a pre-revenue, development-stage micro-cap, so the risks are severe and concentrated. Its products are early-stage and could fail in clinical or regulatory testing, leaving little or no commercial value. As a single-platform company it has limited diversification, and it has no approved products, no revenue, and ongoing operating losses, meaning it depends on raising more capital; its $50 million shelf and prior placements point to dilution that can erode existing shareholders. It has already navigated a Nasdaq listing compliance process and a cancelled reverse split, both signs of the financial fragility common to companies this small. The shares are thinly traded and highly volatile, and an investment could result in substantial or total loss.
How is Polyrizon Ltd. (PLRZ) valued? (approximate, Full-year 2025 results)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Polyrizon Ltd.'s investor relations page or your broker.
- Product revenue: None (development-stage)
- Operating loss (2025): ~$6.2 million
- Accumulated deficit: ~$8.4 million
- Cash (end of 2025): ~$17.5 million, no debt
- Market cap: ~$20-25 million (micro-cap, varies)
- Valuation basis: Early-stage pipeline optionality
For a pre-revenue biotech like Polyrizon there are no earnings or P/E to analyze; the market value reflects speculation on whether products such as NASARIX can eventually reach the market, not current profits. The most important numbers are cash versus burn rate, which together indicate how long the company can operate before needing to raise more money. With about $17.5 million in cash against roughly $6 million in annual operating losses, runway looks adequate for now, but the shelf registration and small share count mean future financings could significantly dilute existing holders. Figures are approximate and can change quickly for a company this small.
Who competes with Polyrizon Ltd. (PLRZ)?
Nasal allergy and barrier products
Established allergy relief and nasal-barrier products from large consumer-health and pharma companies (for example branded nasal sprays and powder barriers) target the same allergy sufferers Polyrizon hopes to reach, with far greater scale, distribution, and proven products.
Intranasal drug-delivery developers
Other small and mid-size biotechs working on intranasal and mucoadhesive drug-delivery technologies compete for similar scientific validation, partnerships, and investor attention, and many are better funded or further along than Polyrizon.
ETFs and alternatives
Broad biotech ETFs such as the SPDR S&P Biotech ETF (XBI) or iShares Biotechnology ETF (IBB) offer diversified exposure to the sector, but micro-caps like Polyrizon are rarely held in major ETFs, so most index exposure to it is minimal or nonexistent.
How to invest in Polyrizon Ltd. (PLRZ)
There are three common ways to get PLRZ exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so PLRZ sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where PLRZ fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Polyrizon Ltd. (PLRZ)
Polyrizon is an early-stage, pre-revenue nasal-hydrogel biotech whose value rests on unproven products like NASARIX (PL-14) reaching the market years from now. It behaves like a highly speculative micro-cap: thinly traded, news-driven, and capable of large swings in either direction, with a real possibility of substantial or total loss.
More on Polyrizon Ltd. (PLRZ)
Whether PLRZ is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PLRZ a buy?, and where the stock could go from here in the PLRZ stock forecast.
For income investors, whether PLRZ pays a dividend and how the payout looks is covered in does PLRZ pay a dividend?
Build a basket around PLRZ with Walnut
Use Polyrizon Ltd. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Polyrizon Ltd. do?
+
Polyrizon is a development-stage Israeli biotech that develops intranasal hydrogel products delivered as nasal sprays. Its Capture and Contain technology is designed to form a thin protective barrier in the nasal cavity against allergens and viruses, while its Trap and Target platform aims to improve nasal drug delivery. Its lead program is the NASARIX (PL-14) allergy blocker. It has no approved products and no revenue yet.
What is NASARIX (PL-14)?
+
NASARIX (PL-14) is Polyrizon's most advanced product candidate, an allergy blocker based on its hydrogel barrier technology. The company has been advancing it toward human studies, signing U.S. clinical sites for a seasonal allergic-rhinitis study, arranging a nasal-residence-time study, and pursuing an FDA pre-submission pathway. It is still in development and has not been approved or cleared for sale.
Does PLRZ pay a dividend?
+
No. Polyrizon does not pay a dividend. As an early-stage, pre-revenue biotech, it reinvests all available capital into research and development and preserves cash to fund its studies, so any potential return to shareholders would come only from share-price changes, not income.
Is PLRZ profitable?
+
No. Polyrizon is a development-stage company with no product revenue, so it operates at a loss while it funds research. It reported an operating loss of roughly $6.2 million for 2025 and ended the year with about $17.5 million in cash and no debt. It will likely need to raise additional capital before any product could reach the market.
Why is PLRZ stock so volatile?
+
Polyrizon is a thinly traded micro-cap whose value depends on unproven, early-stage products. Its price can swing sharply on press releases, clinical or regulatory updates, financings, and general sentiment toward small biotechs. Low trading volume and a small share count amplify these moves, which is typical for highly speculative development-stage stocks.
Is PLRZ a good stock?
+
This is descriptive, not advice. The bull case is that a novel non-invasive nasal barrier like NASARIX could address allergy and viral-exposure markets, supported by cash on hand and an advancing clinical plan. The bear case is that it is a pre-revenue micro-cap with unproven products, ongoing losses, dilution risk, and a real chance of substantial or total loss. Whether it fits you depends on your own goals and risk tolerance.
Is PLRZ a good stock to buy right now?
+
This is informational, not a recommendation. Polyrizon is a highly speculative, early-stage biotech, so any position carries high risk and high volatility, and timing around clinical or financing news is inherently uncertain. Walnut provides information, not investment advice. Consider your own objectives, risk tolerance, and whether you can afford a possible total loss before deciding.
Which ETFs or baskets include PLRZ?
+
Very few, if any, major ETFs hold Polyrizon because it is a micro-cap that generally falls below the size and liquidity thresholds of broad biotech funds like XBI or IBB. Most investors who want exposure buy the shares directly. In Walnut you could include PLRZ as one holding in a thematic basket, such as a speculative biotech theme, while sizing it small to manage risk.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Polyrizon Ltd.'s investor relations page or your broker before making investment decisions.